SCHEMBL2017661

SCHEMBL2017661

CC(C)(C)OC(=O)N1CCC(n2nnnc2-c2cn3c4c(cccc24)CCC3)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GPR119 Q8TDV5 3/20 0.39
MTNR1A P48039 2/20 0.39
MTNR1B P49286 2/20 0.39
PRKCG P05129 1/20 0.38
PRKCB P05771 1/20 0.38
PRKCA P17252 1/20 0.38
PRKCH P24723 1/20 0.38
PRKCE Q02156 1/20 0.38
PRKCD Q05655 1/20 0.38
NR3C1 P04150 1/20 0.37
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37
PIK3CG P48736 1/20 0.37
ATR Q13535 1/20 0.37
AURKB Q96GD4 1/20 0.37
KDM1A O60341 2/20 0.37
STS P08842 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12475122 0.81 HTR2A (0.39) MTNR1AMTNR1B
SCHEMBL12572709 0.81 HTR2C (0.39) MTNR1AMTNR1B
Hydrochloric Acid SCHEMBL2019691 0.81 HTR2C (0.38) MTNR1AMTNR1BLMNA
SCHEMBL2019928 0.80 HTR2A (0.41) MTNR1AMTNR1B
SCHEMBL2016940 0.78 HTR2C (0.38) MTNR1AMTNR1B
SCHEMBL2018084 0.75 HTR2C (0.37) MTNR1AMTNR1B
SCHEMBL2018775 0.74 POLB (0.51) NPC1RAB9AMTNR1AMTNR1BLMNA
SCHEMBL2017372 0.72 EGFR (0.50) GPR119KDM1A
SCHEMBL16399744 0.71 GPR119 (0.47) GPR119NR3C1TP53
SCHEMBL6806993 0.70 GSK3B (0.58) PRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 NPC1 235/4885RAB9A 1649/4885GPR119 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.